专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010070074A3 EVALUATION OF THE POTENTIAL RISK OF DRUG INDUCED MOOD DISTURBANCE AND SUICIDE: USE OF A DEDICATED PLATFORM 审中-公开
标题翻译：评估药物诱发的情绪失调和自杀的潜在风险：使用专用平台
公开(公告)号：WO2010070074A3
公开(公告)日：2010-10-07
申请号：PCT/EP2009067464
申请日：2009-12-17
申请人： BIOCORTECH , WEISSMANN DINAH , PUJOL JEAN-FRANCOIS , VINCENT LAURENT , CAVAREC LAURENT
发明人： WEISSMANN DINAH , PUJOL JEAN-FRANCOIS , VINCENT LAURENT , CAVAREC LAURENT
IPC分类号： C12Q1/68 , G01N33/573
CPC分类号： C12Q1/6881 , C12Q1/6883 , C12Q2600/142 , C12Q2600/158 , G01N33/5014 , G01N33/5058 , G01N33/942 , G01N2800/302 , G01N2800/303 , G01N2800/304
摘要： The present invention relates to in vitro methodsfor the determination of the potential toxicity of test compounds. The invention also comprises in vitro methods for the selection of therapeutical compounds useful for the treatment of pathology related to an alteration of the mechanism of the mRNA editing of ADAR dependent A to I mRNA editing of the serotonin 2C receptor (5HTR2C). Finally, the present invention is directed to the kits and tools for the implementation of these methods. The invention is of special utility in the pharmaceutical industry for analysis of the toxicity profile or the screening of compounds involved in drug development and/or in pharmaceutical compositions.
摘要翻译：本发明涉及用于测定测试化合物的潜在毒性的体外方法。本发明还包括用于选择治疗化合物的体外方法，所述治疗化合物用于治疗与改变ADAR依赖性A至I mRNA编辑血清素2C受体（5HTR2C）的mRNA编辑机制有关的病理学。最后，本发明针对用于实施这些方法的试剂盒和工具。本发明在制药工业中用于分析药物开发中涉及的化合物和/或药物组合物的毒性分布或筛选方面是特别有用的。

2. 发明申请

WO2005103047A8 DERIVATIVES OF 14.15-DIHYDRO 20.21-DINOREBURNAMENIN-14-OL, AND APPLICATIONS THEREOF 审中-公开
标题翻译： 14.15-二氢O O O O O IN IN IN IN IN IN IN IN IN IN IN IN IN IN IN IN OF OF OF OF OF OF OF OF OF OF OF OF OF OF OF OF OF OF
公开(公告)号：WO2005103047A8
公开(公告)日：2006-11-16
申请号：PCT/FR2005000902
申请日：2005-04-14
申请人： BIOCORTECH , CIAPETTI PAOLA , DEYON LAURENCE , WERMUTH CAMILLE-GEORGES , PUJOL JEAN-FRANCOIS , WEISSMANN DINAH
发明人： CIAPETTI PAOLA , DEYON LAURENCE , WERMUTH CAMILLE-GEORGES , PUJOL JEAN-FRANCOIS , WEISSMANN DINAH
IPC分类号： C07D461/00 , A61K31/437 , A61P25/18 , A61P25/24
CPC分类号： C07D461/00
摘要： The invention relates to novel derivatives of 14,15-dihydro 20,21 dinoreburnamenin-14-ol, having formula (I), in which R represents a radical -AR', wherein A represents a heteroatom and R' represents a group selected from the group comprising alkyl radicals at C 1 -C 6 , alkenyls at C 1 -C 6 , alkynyls at C 1 -C 6 , aralkyls; esters having formula -R 1 -CO-O-R 2 ; amides having formula -R 3 -CO-NZY, wherein Y and Z together can form a cycloalkyl radical or a heterocyclic radical, optionally substituted by one or more alkyl radicals; a radical selected from the group comprising alkyl radicals, alkenyls or alkynyls, substituted by at least one amine having formula -NZY; or one of the pharmaceutically-acceptable salts thereof, including the isomers, enantiomers and diastereoisomers thereof and mixtures of same. The invention also relates to the use of said novel derivatives for the preparation of a pharmaceutical composition which is intended, in particular, for the treatment and/or prevention of depression, sleep/wake cycle disorders and symptomatic frontal disorders in cognitive components among humans.
摘要翻译：本发明涉及具有式（I）的14,15-二氢20,21二辛烷亚胺-14-醇的新衍生物，其中R表示一个自由基-AR'，其中A表示杂原子，R'表示选自 C 1 -C 6烷基，C 1 -C 6亚烷基，C 1 -C 6亚烷基，C 1 -C 6亚烷基，C 1 -C 6亚烷基， C 1 -C 6 - 芳烷基; 具有式-R 1 -CO-O-R 2的酯; 具有式-R 3 -CO-NZY的酰胺，其中Y和Z一起可以形成任选被一个或多个烷基取代的环烷基或杂环基; 选自由至少一个具有式-NZY的胺取代的烷基，烯基或炔基的基团; 或其药学上可接受的盐之一，包括其异构体，对映体和非对映异构体及其混合物。本发明还涉及所述新型衍生物用于制备药物组合物的用途，该药物组合物特别用于治疗和/或预防人类中认知成分中的抑郁症，睡眠/觉醒周期障碍和症状性正面疾病。

3. 发明专利

AT488516T 未知
公开(公告)号：AT488516T
公开(公告)日：2010-12-15
申请号：AT05757149
申请日：2005-04-14
申请人： BIOCORTECH
发明人： CIAPETTI PAOLA , DEYON LAURENCE , WERMUTH CAMILLE-GEORGES , PUJOL JEAN-FRANCOIS , WEISSMANN DINAH
IPC分类号： C07D461/00 , A61K31/437 , A61P25/18 , A61P25/24
摘要： The invention relates to novel derivatives of 14,15-dihydro 20,21-dinoreburnamenin-14-ol, having formula (I) in which R represents a radical -AR' wherein A represents a heteroatom and R' represents a group selected from the group comprising linear or branched C 1 -C 6 alkyl radicals, C 2 -C 6 alkenyls, C 2 -C 6 alkynyls, arylalkyls; esters comprising the formula -R 1 - CO-O-R 2 ; amides comprising the formula -R 3 -CO-NZY, wherein Y and Z together can form a cycloalkyl radical or a heterocyclic radical, optionally substituted by one or more alkyl radicals; a radical selected from the group comprising alkyl radicals, alkenyls or alkynyls, substituted by at least one amine with formula -NZY; or one of the pharmaceutically-acceptable salts thereof, including the isomers, enantiomers and diastereoisomers thereof and mixtures thereof. The invention also relates to the use of the novel derivatives for the preparation of a pharmaceutical composition which is intended, in particular, for the treatment and/or prevention of depression, sleep-wake cycle disorders and symptomatic frontal disorders in cognitive components among humans.

4. 发明专利

CA2747322C EVALUATION OF THE POTENTIAL RISK OF DRUG TOXICITY OR SIDE-EFFECTS BASED ON QUANTITATIVE EXPRESSION OF ADAR EDITING ENZYMES AND 5HT2CR ISOFORMS 未知
公开(公告)号：CA2747322C
公开(公告)日：2021-09-28
申请号：CA2747322
申请日：2009-12-17
申请人： BIOCORTECH
发明人： WEISSMANN DINAH , PUJOL JEAN-FRANCOIS , VINCENT LAURENT , CAVAREC LAURENT
IPC分类号： C12Q1/68 , C12Q1/6809 , C12Q1/6876
摘要： The present invention relates to in vitro methodsfor the determination of the potential toxicity of test compounds. The invention also comprises in vitro methods for the selection of therapeutical compounds useful for the treatment of pathology related to an alteration of the mechanism of the mRNA editing of ADAR dependent A to I mRNA editing of the serotonin 2C re-ceptor (5HTR2C). Finally, the present invention is directed to the kits and tools for the implementation of these methods. The in-vention is of special utility in the pharmaceutical industry for analysis of the toxicity profile or the screening of compounds in-volved in drug development and/or in pharmaceutical compositions.

5. 发明专利

CA2554436C UTILISATION DU 14,15-DIHYDRO 20,21-DINOREBURNAMENIN14-OL POUR TRAITER ET/OU PREVENIR LES DEPRESSIONS MAJEURES ET LES DESORDRES DU CYCLE VEILLE-SOMMEIL 未知
公开(公告)号：CA2554436C
公开(公告)日：2014-07-15
申请号：CA2554436
申请日：2005-01-27
申请人： BIOCORTECH
发明人： PUJOL JEAN-FRANCOIS , WEISSMANN DINAH
IPC分类号： A61K31/437 , A61K31/4545
摘要： L'invention a pour objet une nouvelle application thérapeutique du 14,15-dihydro 20,21-dinoréburnaménin 14-ol de formule (I) (voir formule I) pour le traitement des dépressions majeures chez l'Homme, notamment pour le traitement de patient résistant aux traitements antidépresseurs classiques, ou pour le traitement des désordres du cycle veille-sommeil.

6. 发明专利

FR2865650B1 未知
公开(公告)号：FR2865650B1
公开(公告)日：2008-06-13
申请号：FR0403694
申请日：2004-04-08
申请人： BIOCORTECH
发明人： PUJOL FRANCOIS , WEISSMANN DINAH
IPC分类号： A61K31/4545 , A61K31/437 , A61P25/00

7. 发明专利

HK1106502A1 未知
公开(公告)号：HK1106502A1
公开(公告)日：2008-03-14
申请号：HK07111220
申请日：2007-10-17
申请人： BIOCORTECH
发明人： CIAPETTI PAOLA , DEYON LAURENCE , WERMUTH CAMILLE-GEORGES , PUJOL JEAN-FRANCOIS , WEISSMANN DINAH
IPC分类号： A61K20060101 , A61P20060101 , C07D20060101 , C07D461/00
摘要： The invention relates to novel derivatives of 14,15-dihydro 20,21-dinoreburnamenin-14-ol, having formula (I) in which R represents a radical -AR' wherein A represents a heteroatom and R' represents a group selected from the group comprising linear or branched C 1 -C 6 alkyl radicals, C 2 -C 6 alkenyls, C 2 -C 6 alkynyls, arylalkyls; esters comprising the formula -R 1 - CO-O-R 2 ; amides comprising the formula -R 3 -CO-NZY, wherein Y and Z together can form a cycloalkyl radical or a heterocyclic radical, optionally substituted by one or more alkyl radicals; a radical selected from the group comprising alkyl radicals, alkenyls or alkynyls, substituted by at least one amine with formula -NZY; or one of the pharmaceutically-acceptable salts thereof, including the isomers, enantiomers and diastereoisomers thereof and mixtures thereof. The invention also relates to the use of the novel derivatives for the preparation of a pharmaceutical composition which is intended, in particular, for the treatment and/or prevention of depression, sleep-wake cycle disorders and symptomatic frontal disorders in cognitive components among humans.

8. 发明专利

CA2554436A1 UTILISATION DU 14,15-DIHYDRO 20,21-DINOREBURNAMENIN14-OL POUR TRAITER ET/OU PREVENIR LES DEPRESSIONS MAJEURES ET LES DESORDRES DU CYCLE VEILLE-SOMMEIL 未知
公开(公告)号：CA2554436A1
公开(公告)日：2005-09-09
申请号：CA2554436
申请日：2005-01-27
申请人： BIOCORTECH
发明人： PUJOL JEAN-FRANCOIS , WEISSMANN DINAH
IPC分类号： A61K31/437 , A61K31/4545
摘要： L'invention a pour objet une nouvelle application thérapeutique du 14,15- dihydro 20,2 1 -dinoréburnaménin 1 4-ol pour le traitement des dépressions majeures chez l'Homme, notamment pour le traitement de patient résistant aux traitements antidépresseurs classiques, ou pour le traitement des désordres du cycle veille-sommeil.

9. 发明专利

FR2865649A1 Use of 14,15-dihydro-20,21-dinor-14-eburnameninol to prepare a pharmaceutical composition for treating or preventing major depression 未知
公开(公告)号：FR2865649A1
公开(公告)日：2005-08-05
申请号：FR0400905
申请日：2004-01-30
申请人： BIOCORTECH
发明人： PUJOL JEAN FRANCOIS , WEISSMANN DINAH
IPC分类号： A61K31/437 , A61K31/4375 , A61P25/24
摘要： 14,15-Dihydro-20,21-dinor-14-eburnameninol (I) is used to prepare a pharmaceutical composition for treating or preventing major depression. 14,15-Dihydro-20,21-dinor-14-eburnameninol of formula (I), where the hydrogens at positions 3 and 16 are trans and the hydroxy group is in alpha or beta conformation, is used to prepare a pharmaceutical composition for treating or preventing major depression. An independent claim is also included for the use of (I) to prepare a pharmaceutical composition for treating patients with depression resistant to conventional antidepressants in order to make such patients sensitive to conventional antidepressant treatment. [Image] ACTIVITY : Antidepressant. No biological data given. MECHANISM OF ACTION : None given.

10. 发明专利

CA2690909C PERIPHERICAL TISSUE SAMPLE CONTAINING CELLS EXPRESSING THE 5HTR2C AND/OR ADARS AS MARKERS OF THE ALTERATION OF THE MECHANISM OF THE 5HTR2C MRNA EDITING AND ITS APPLICATIONS 未知
公开(公告)号：CA2690909C
公开(公告)日：2022-01-18
申请号：CA2690909
申请日：2008-06-13
申请人： BIOCORTECH
发明人： WEISSMANN DINAH , PUJOL JEAN-FRANCOIS , VINCENT LAURENT , CAVAREC LAURENT , MANN JOHN
IPC分类号： C12Q1/686
摘要： The present invention relates to an in vitro method for predicting a pathology related to an alteration of the mechanism of the mRNA editing of ADAR dependent A to I mRNA editing, particularly the serotonin 2C receptor (5HTR2C), in a patient from a peripherical tissue sample containing cells expressing said mRNA, such as the 5HTR2C mRNA, and/or adenosine deaminases acting on RNA (ADARs), such as skin and/or blood tissue sample. The present invention further comprises a method for identifying if an agent is capable of in vivo modifying the editing of the 5HTR2C mRNA in brain tissue or to control the efficiency of a drug intended to prevent or to treat a pathology related to an alteration of the mechanism of the 5HTR2C mRNA editing brain tissue, these methods comprising the implementation of said peripherical tissue markers. In a particular aspect, the present invention relates to such methods wherein the 5HTR2C mRNA editing rate or profile, when it is necessary, is determined by a single strand conformation polymorphism (SSCP) method after amplification by a PCR, preferably by a nested PCR, of the specific mRNA fragment containing the edition sites, making it possible, under given analytical conditions, to obtain the editing rate and/or profile of this edited 5HTR2C mRNA from said peripherical tissue. Finally the invention relates to particular nucleic acid primers implemented in said nested PCR.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式